General Information of Drug Off-Target (DOT) (ID: OT0SKNTG)

DOT Name Parkinson disease protein 7 (PARK7)
Synonyms Maillard deglycase; Oncogene DJ1; Parkinsonism-associated deglycase; Protein DJ-1; DJ-1; Protein/nucleic acid deglycase DJ-1; EC 3.1.2.-, EC 3.5.1.-, EC 3.5.1.124
Gene Name PARK7
Related Disease
Parkinson disease ( )
Autosomal recessive early-onset Parkinson disease 7 ( )
Young-onset Parkinson disease ( )
UniProt ID
PARK7_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1J42 ; 1P5F ; 1PDV ; 1PDW ; 1PE0 ; 1Q2U ; 1SOA ; 1UCF ; 2OR3 ; 2R1T ; 2R1U ; 2R1V ; 2RK3 ; 2RK4 ; 2RK6 ; 3B36 ; 3B38 ; 3B3A ; 3BWE ; 3CY6 ; 3CYF ; 3CZ9 ; 3CZA ; 3EZG ; 3F71 ; 3SF8 ; 4BTE ; 4MNT ; 4MTC ; 4N0M ; 4N12 ; 4OGF ; 4OQ4 ; 4P2G ; 4P34 ; 4P35 ; 4P36 ; 4RKW ; 4RKY ; 4S0Z ; 4ZGG ; 5IP5 ; 5SY6 ; 5SY9 ; 5SYA ; 6AF5 ; 6AF7 ; 6AF9 ; 6AFA ; 6AFB ; 6AFC ; 6AFD ; 6AFE ; 6AFF ; 6AFG ; 6AFH ; 6AFI ; 6AFJ ; 6AFL ; 6E5Z ; 6M8Z ; 7C62 ; 7PA2 ; 7PA3
EC Number
3.1.2.-; 3.5.1.-; 3.5.1.124
Pfam ID
PF01965
Sequence
MASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLED
AKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFG
SKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQ
VKAPLVLKD
Function
Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease. It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway. Has been described as a protein and nucleotide deglycase that catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals. But this function is rebuted by other works. As a protein deglycase, repairs methylglyoxal- and glyoxal-glycated proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteine, arginine and lysine residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) that cause irreversible damage. Also functions as a nucleotide deglycase able to repair glycated guanine in the free nucleotide pool (GTP, GDP, GMP, dGTP) and in DNA and RNA. Is thus involved in a major nucleotide repair system named guanine glycation repair (GG repair), dedicated to reversing methylglyoxal and glyoxal damage via nucleotide sanitization and direct nucleic acid repair. Protects histones from adduction by methylglyoxal, controls the levels of methylglyoxal-derived argininine modifications on chromatin. Able to remove the glycations and restore histone 3, histone glycation disrupts both local and global chromatin architecture by altering histone-DNA interactions as well as histone acetylation and ubiquitination levels. Displays a very low glyoxalase activity that may reflect its deglycase activity. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells. In pancreatic islets, involved in the maintenance of mitochondrial reactive oxygen species (ROS) levels and glucose homeostasis in an age- and diet dependent manner. Protects pancreatic beta cells from cell death induced by inflammatory and cytotoxic setting. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity. In macrophages, interacts with the NADPH oxidase subunit NCF1 to direct NADPH oxidase-dependent ROS production, and protects against sepsis.
Tissue Specificity
Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain (at protein level). Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Expressed by pancreatic islets at higher levels than surrounding exocrine tissues .
KEGG Pathway
Parkinson disease (hsa05012 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Reactome Pathway
Chaperone Mediated Autophagy (R-HSA-9613829 )
Late endosomal microautophagy (R-HSA-9615710 )
Aggrephagy (R-HSA-9646399 )
SUMOylation of transcription cofactors (R-HSA-3899300 )
BioCyc Pathway
MetaCyc:ENSG00000116288-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Parkinson disease DISQVHKL Definitive Autosomal recessive [1]
Autosomal recessive early-onset Parkinson disease 7 DISQVZFT Strong Autosomal recessive [2]
Young-onset Parkinson disease DIS05LFS Supportive Autosomal recessive [3]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 2 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Doxorubicin DMVP5YE Approved Parkinson disease protein 7 (PARK7) decreases the response to substance of Doxorubicin. [17]
MG-132 DMKA2YS Preclinical Parkinson disease protein 7 (PARK7) decreases the response to substance of MG-132. [18]
------------------------------------------------------------------------------------
This DOT Affected the Regulation of Drug Effects of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Glutathione DMAHMT9 Approved Parkinson disease protein 7 (PARK7) increases the abundance of Glutathione. [18]
------------------------------------------------------------------------------------
15 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate affects the expression of Parkinson disease protein 7 (PARK7). [4]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of Parkinson disease protein 7 (PARK7). [5]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Parkinson disease protein 7 (PARK7). [6]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Parkinson disease protein 7 (PARK7). [7]
Hydrogen peroxide DM1NG5W Approved Hydrogen peroxide increases the expression of Parkinson disease protein 7 (PARK7). [8]
Vorinostat DMWMPD4 Approved Vorinostat decreases the expression of Parkinson disease protein 7 (PARK7). [9]
Menthol DMG2KW7 Approved Menthol decreases the expression of Parkinson disease protein 7 (PARK7). [10]
Lindane DMB8CNL Approved Lindane decreases the activity of Parkinson disease protein 7 (PARK7). [11]
Sodium phenylbutyrate DMXLBCQ Approved Sodium phenylbutyrate increases the expression of Parkinson disease protein 7 (PARK7). [12]
Pyrethroids DM1794O Phase 2 Pyrethroids decreases the activity of Parkinson disease protein 7 (PARK7). [11]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the expression of Parkinson disease protein 7 (PARK7). [13]
Paraquat DMR8O3X Investigative Paraquat decreases the activity of Parkinson disease protein 7 (PARK7). [11]
[3H]methyltrienolone DMTSGOW Investigative [3H]methyltrienolone increases the expression of Parkinson disease protein 7 (PARK7). [15]
Butanoic acid DMTAJP7 Investigative Butanoic acid increases the expression of Parkinson disease protein 7 (PARK7). [12]
NSC-1771 DMNXDGQ Investigative NSC-1771 decreases the activity of Parkinson disease protein 7 (PARK7). [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Drug(s)
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the methylation of Parkinson disease protein 7 (PARK7). [14]
[3H]CP55940 DMU7FC5 Investigative [3H]CP55940 increases the oxidation of Parkinson disease protein 7 (PARK7). [16]
------------------------------------------------------------------------------------

References

1 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
2 The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
3 Role of mendelian genes in "sporadic" Parkinson's disease. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S66-70. doi: 10.1016/S1353-8020(11)70022-0.
4 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
5 Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
6 Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
7 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
8 DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 2001 Dec;35(6):885-93. doi: 10.1080/10715760100301381.
9 Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010 Aug;6(6):711-24. doi: 10.4161/auto.6.6.12397. Epub 2010 Aug 17.
10 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
11 Inhibition by pesticides of the DJ-1/Park7 protein related to Parkinson disease. Toxicology. 2023 Mar 15;487:153467. doi: 10.1016/j.tox.2023.153467. Epub 2023 Feb 24.
12 Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem. 2011 Apr 29;286(17):14941-51. doi: 10.1074/jbc.M110.211029. Epub 2011 Mar 3.
13 Benzo(a)pyrene exposure in utero exacerbates Parkinson's Disease (PD)-like -synucleinopathy in A53T human alpha-synuclein transgenic mice. Toxicol Appl Pharmacol. 2021 Sep 15;427:115658. doi: 10.1016/j.taap.2021.115658. Epub 2021 Jul 29.
14 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
15 Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics. 2007 Jan;7(1):47-63.
16 Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H(2)O(2) signaling mechanism. Leuk Res. 2020 Aug;95:106389. doi: 10.1016/j.leukres.2020.106389. Epub 2020 May 26.
17 Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer. Toxicol Sci. 2014 Jun;139(2):396-406. doi: 10.1093/toxsci/kfu051. Epub 2014 Mar 27.
18 Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem. 2008 Jun 1;105(6):2435-53. doi: 10.1111/j.1471-4159.2008.05333.x.